OUR BUSINESS

  1. Home
  2. Our Business

Kyowa Pharmaceutical is focusing on not only medicines in the CNS area but also DTx (digital therapeutics) as a new treatment method next to pharmaceuticals and medical devices. We aim to become a CNS total solution company that comprehensively supports patients and their families throughout their lives, including prevention of pre-illness, realization of healthy longevity, treatment, and prognosis, by combining digital technology and digital technology with existing medicines.

Products

KYOWA manufactures and distributes generic drugs focused on the central nervous system (CNS) domain and long-listed drugs (i.e., branded drugs with expired patent-protected exclusivity periods), and distributes newly approved drugs. Its generic drugs are well-known as AMEL, KYOWA’s branded products.

CNS drugs
Total number of products 137 ingredients 352 items
(As of March 2021)

Neuropsychiatric drugs

29 ingredients 125 items

Neuropsychiatric drugs

Antiparkinsonian drugs

9 ingredients 18 items

Antiparkinsonian drugs

Sedative-hypnotics, anxiolytics

13 ingredients 29 items

Sedative-hypnotics, anxiolytics

Antiepileptics

7 ingredients 20 items

Antiepileptics

Other CNS drugs

5 ingredients 25 items

Other CNS drugs

Breakdown of Products by Therapeutic Category

Breakdown of Products by Therapeutic Category

(As of March 2021)